

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (cancelled).

Claim 6 (Currently Amended): A method of treatment ~~or prophylaxis~~ of ischemic heart disease, comprising administering to a patient who is in need of such a treatment ~~or prophylaxis~~ a substance, as an active ingredient, which can increase intracellular cyclic guanosine 3',5'-monophosphate (cGMP) production by acting on a natriuretic peptide receptor, and which has an effect of reducing an infarct region, ~~before the initiation of~~, during and/or following ischemia reperfusion therapy.

Claim 7 (Currently Amended): The method of claim 6, wherein ischemia-reperfusion injury is ~~suppressed~~ reduced in the treatment of ischemic heart disease.

Claim 8 (previously presented): The method of claim 6, wherein the ischemic heart disease is myocardial infarction.

Claim 9 (previously presented): The method of claim 6, wherein the substance as the active ingredient is a natriuretic peptide or its salt.

Claim 10 (original): The method of claim 9, wherein the natriuretic peptide is atrial natriuretic peptide.

Claim 11 (Currently Amended): A method for reducing an infarct region or suppressing enlargement of an infarct region in the heart of a patient who is suffering from ~~or has a potential~~

risk of suffering from infarct resulting from ischemic necrosis as an ischemia reperfusion injury, wherein said method comprises:

administering a substance acting on a natriuretic peptide receptor to increase the production of cellular cyclic guanosine 3',5'-monophosphate (cGMP), at an amount effective for reducing the infarct region or suppressing enlargement of an infarct region to said patient ~~before the initiation of~~, during and/or following ischemia reperfusion.

Claim 12 (previously presented): A method of claim 11, wherein the substance is a natriuretic peptide comprising atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) or C-type natriuretic peptide (CNP).

Claim 13 (previously presented): A method of claim 12, wherein the substance is administered at a dose between 0.01 $\mu\text{g}/\text{kg}/\text{ml}$ and 0.2 $\mu\text{g}/\text{kg}/\text{ml}$ by continuous infusion.

Claim 14 (previously presented): A method of claim 13, wherein the substance is administered at a dose between 0.025 $\mu\text{g}/\text{kg}/\text{ml}$ and 0.1 $\mu\text{g}/\text{kg}/\text{ml}$.

Claim 15 (previously presented): A method of any one of claims 12, 13 and 14, wherein administration is by an intravenous injection.

Claim 16 (previously presented): A method by any one of claims 12, 13 and 14, wherein administration is by a coronary injection.